This study evaluates a new aqueous nasal formulation of ipratropium bromide (Atrovent Nasal Spray 0.03%) in subjects with perennial non-allergic rhinitis in a double-blind, placebo-controlled trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback